drugset / Trial / NCT05464628

Drug Interaction Study of ASC42 With Atorvastatin

NCT05464628

Phase 1 Completed 12 enrolled Gannex Pharma Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to determine whether ASC42 alters the pharmacokinetics of atorvastatin in healthy subjects.

Timeline

Start
2022-08-08
Primary completion
2022-08-23
Completion
2022-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ASC42 Unknown
Subject Atorvastatin Small molecule

Indications

No indication recorded.